NeOnc Technologies Holdings, Inc. NTHI 深 滬
交易中 07-18 11:54:44 美东时间
4.2701
-0.140
-3.17%
華盛通- 最 高4.41
- 今 開4.40
- 成交量 4204股
- 最 低 4.2669
- 昨 收 4.41
- 總市值 8124.63万
- 52周最高 25.00
- 市盈率 靜 --
- 換手率 0.02%
- 52周最低 3.20
- 委 比 56.71%
- 總股本 1902.68万
- 歷史最高 25.00
- 量 比 0.17
- 振 幅 3.24%
- 歷史最低 3.20
- 每 手 1
- 風險率 3.13%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多12 Health Care Stocks Moving In Monday's Pre-Market Session
Gainers Sonnet BioTherapeutics (NASDAQ:SONN) shares rose 239.4% to $17.55 dur...
07-14 20:08
NeOnc Technologies Announces UAE Investment Partnership
An update from NeOnc Technologies Holdings, Inc. ( ($NTHI) ) is now available. ...
07-11 05:30
NeOnc Technologies joins Russell Microcap Index
NeOnc Technologies (NASDAQ:NTHI) said on Wednesday that it has joined the Russell Microcap Index following the conclusion of the 2025 Russell indexes annual reconstitution. The annual Russell US Index...
07-09 21:19
NeOnc Technologies Holdings, Inc. Joins Russell Microcap® Index
NeOnc Technologies Holdings, Inc. (NASDAQ: NTHI), a biopharmaceutical company specializing in treatments for central nervous system (CNS) cancers, has been added to the Russell Microcap® Index following the 2025 annual reconstitution. The Russell Microcap® Index includes small-capitalization U.S. companies, with an average market cap of about $640 million. Membership in the index is a validation of NeOnc's progress and commitment to advancing its...
07-09 13:00
NeOnc Technologies Signs $50 Million Non-Binding Strategic Term Sheet with Quazar Investment to Launch GCC & MENA Expansion and Clinical Trials Platform
NeOnc Technologies Holdings, Inc. has signed a non-binding term sheet with Quazar Investment to form NuroMENA Holdings Ltd, focusing on clinical trials in the MENA region. The partnership includes a $50 million equity investment, with 70% allocated to acquiring NeOnc shares and 30% for clinical trials and infrastructure development. NeOnc and NuroCure will execute a sub-license agreement for NEO100 and NEO212, targeting brain cancers. The transac...
07-08 13:00
NeOnc Technologies Names Josh Neman CCO; Says Appointment Bolsters FDA Approval Path While Company Explores AI And Quantum Computing To Enhance Drug Delivery Platform
USC brain tumor authority to accelerate four clinical trials including lead asset NEO100 nearing Phase 2a completion ahead of scheduleAppointment bolsters FDA approval path while company explores AI and quantum computing
06-06 21:07
NeOnc Technologies Holdings, Inc. Appoints Dr. Josh Neman as Chief Clinical Officer to Advance Clinical Strategy and Translational Oncology Programs
<p><p><em>USC脑肿瘤权威将加速四项临床试验，其中领先资产NEO100即将提前完成IIa期试验</em></p> <p><em>任命进一步巩固FDA批准路径，同时公司探索AI和量子计算以增强药物递送平台</em></p> <p>NeOnc Technologies Holdings, Inc.宣布任命Josh Neman博士为首席临床官（CCO）。Neman博士在癌症神经科学和转化研究领域拥有深厚背景，将在NeOnc推动临床开发战略，加速四项临床试验，尤其是即将完成IIa期的NEO100资产。公司同时探索AI和量子计算技术以提升药物递送平台。</p></p>
06-06 13:00
NeOnc Technologies Holdings Appoints Executive Chairman Amir Heshmatpour As Company's New President
CALABASAS, Calif., April 10, 2025 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NASDAQ:NTHI), a clinical-stage biopharmaceutical company focused on innovative treatments for central nervous system (CNS) cancers
04-10 20:07
12 Health Care Stocks Moving In Wednesday's Intraday Session
Gainers Allakos (NASDAQ:ALLK) stock rose 48.2% to $0.32 during Wednesday's reg...
04-03 01:06
Why Xos Shares Are Trading Higher By Around 9%; Here Are 20 Stocks Moving Premarket
Shares of Xos, Inc. (NASDAQ:XOS) rose sharply in today's pre-market trading aft...
03-31 16:58
